|
Affiliation |
Frontier Science Research Center |
|
External Link |
|
MORISHITA Kazuhiro
|
|
|
Research Areas 【 display / non-display 】
-
Life Science / Pathological biochemistry
-
Life Science / Hematology and medical oncology
-
Life Science / Medical biochemistry
Papers 【 display / non-display 】
-
Identification and tracking of HTLV-1-infected T cell clones in virus-associated neurologic disease.
Nozuma S, Matsuura E, Tanaka M, Kodama D, Matsuzaki T, Yoshimura A, Sakiyama Y, Nakahata S, Morishita K, Enose-Akahata Y, Jacoboson S, Kubota R, Takashima H
JCI insight 8 ( 7 ) 2023.4
Language：English Publishing type：Research paper (scientific journal)
-
Prognostic analysis of smoldering ATLL with skin eruptions based on genomic aberrations.
Mochida K, Nakahata S, Suzuki Y, Inoue K, Moriguchi S, Yamashita A, Amano M, Morishita K
Journal of dermatological science 109 ( 2 ) 80 - 88 2023.2
Language：English Publishing type：Research paper (scientific journal)
-
GPR56 C-terminal fragment mediates signal received by N-terminal fragment of another adhesion GPCR Latrophilin1 in neurons.
Nojima Y, Toriyama M, Tago K, Mizuno N, Morishita K, Itoh H
Genes to cells : devoted to molecular & cellular mechanisms 28 ( 2 ) 83 - 96 2023.2
-
Local cerebral blood flow assessment using transcranial Doppler ultrasonography in a dog with brain infarction in the right middle cerebral artery territory.
Sasaoka K, Ohta H, Ishizuka T, Osuga T, Morishita K, Sasaki N, Takiguchi M
The Journal of veterinary medical science 84 ( 10 ) 1385 - 1390 2022.10
Language：English Publishing type：Research paper (scientific journal)
DOI： 10.1292/jvms.22-0310
-
The CGRP Receptor Antagonist MK0974 Induces EVI1<sup>high</sup> AML Cell Apoptosis by Disrupting ERK Signaling.
Suekane A, Ichikawa T, Saito Y, Nakahata S, Morishita K
Anticancer research 42 ( 10 ) 4743 - 4752 2022.10
Language：English Publishing type：Research paper (scientific journal)
Books 【 display / non-display 】
-
International Symposium on Superconductivity, 山藤 馨, Morishita T. (Tadataka)
Springer-Verlag 1995
Language：Japanese
MISC 【 display / non-display 】
-
ウイルス感染、ゲノム異常と白血病発症機構
森下 和広
宮崎医学会誌 29 ( 1 ) 1 - 7 2005.4
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
The role of CD28 in adult T-cell leukaemia/lymphoma
Nakahata S., Morishita K.
British Journal of Haematology 192 ( 2 ) 235 - 236 2021.1
Language：Japanese Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：British Journal of Haematology
DOI： 10.1111/bjh.17214
-
Shimosaki S., Nakahata S., Ichikawa T., Kitanaka A., Kameda T., Hidaka T., Kubuki Y., Kurosawa G., Zhang L., Sudo Y., Shimoda K., Morishita K.
Biochemical and Biophysical Research Communications 530 ( 2 ) 486 2020.9
Language：Japanese Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Biochemical and Biophysical Research Communications
The authors regret that the day of antibody injection for NOG mice subcutaneously transplanted with MT-2 or HH must be corrected from “every 3 days” to “every 3–4 days” in the part of “Supplementary materials and methods”. The authors also regret that the day of antibody injection for NOG mice subcutaneously transplanted with MT-2 or Su9T01 must be corrected from “two times per week for 2 weeks” to “on day 1, day 8, day 15, and day 21 post-cell injection” in the part of “Supplementary materials and methods”. These corrections do not change the conclusions of this manuscript. The authors would like to apologise for any inconvenience caused. The correct supplementary materials and methods. In vivo experimental therapy studies. Six-to eight-week-old female NOD/Shi-scid/IL-2Rγnull (NOG) or SCID mice (CLEA Japan) were given a single subcutaneous injection of 2 × 106 MT-2 cells or HH cells suspended in 100 μL PBS-diluted matrigel (BD Biosciences). When the average tumor size reached an approximate volume of 100–150 mm3, the mice were intravenously injected with either PBS, mogamulizumab, or the JST-TFR09 antibody at doses of 10 mg/kg (MT-2) or 20 mg/kg (HH) body weight 4–5 times every 3–4 days. The length and width of each tumor were measured with a caliper twice per week and used to calculate the tumor volume (length × width2/2). For Kaplan-Meier survival analysis of mice, NOG mice were given a single intravenous injection of 1 × 106 MT-2 or Su9T01 cells suspended in 100 μL PBS. At 3 days after inoculation of ATLL cells, the mice were intravenously injected with either PBS or JST-TFR09 on day 1, day 8, day 15, and day 21 post-cell injection. The survival rate of mice was observed for a period of 100 days. The authors would like to apologise for any inconvenience caused.
-
Nakahata S., Yamazaki S., Nakauchi H., Morishita K.
Oncogene 30 ( 25 ) 2011.6
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (bulletin of university, research institution) Publisher：Oncogene
DOI： 10.1038/onc.2011.158
-
TCF8遺伝子発現抑制による成人T細胞白血病・リンパ腫発症機構.
中畑新吾, 森下和広
血液フロンティア 2008.6
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：中外医学社
Presentations 【 display / non-display 】
-
Short-form of BCL11B contributes to tumorigenesis of adult T-cell leukemia/lymphoma International conference
Happy Kurnia Permatasari, Shingo Nakahata, Tomonaga Ichikawa, Yusuke Saito, Tomohiko Taki, Masafumi Taniwaki, Kazuhiro Morishita
18th International Conference on Human Retrovirology HTLV and Related Viruses
Event date： 2017.3.7 - 2017.3.10
Language：English Presentation type：Oral presentation (general)
-
Targeting PRMT5 inhibits HSP90A function with induction of tumor-specific apoptosis in NDRG2low ATL and other cancers International conference
Tomonaga Ichikawa, Obeid Shanab, Shingo Nakahata, Hidekatsu Iha, Masaya Ono, Ayako Nakatake, Kuniyo Sakamoto, Kazuhiro Morishita
18th International Conference on Human Retrovirology HTLV and Related Viruses
Event date： 2017.3.7 - 2017.3.10
Language：English Presentation type：Poster presentation
-
Development of complete human IgG antibody against human TFR1 for novel therapy of ATLL International conference
Shingo Nakahata, Tomonaga Ichikawa, Shunsuke Shimosaki, Gene Kurosawa, Lilin Zhang, Yukio Sudo, Kazuya Shimoda, Kazuhiro Morishita
18th International Conference on Human Retrovirology HTLV and Related Viruses
Event date： 2017.3.7 - 2017.3.10
Language：English Presentation type：Poster presentation
-
Short-form of BCL11B contributes to leukemogenesis of adult T-cell leukemia/lymphoma
Happy Kurnia Permatasari, Shingo Nakahata, Tomonaga Ichikawa, Yusuke Saito, Tomohiko Taki, Masafumi Taniwaki, Kazuhiro Morishita
第21回造血器腫瘍研究会
Event date： 2017.2.17 - 2017.2.18
Language：English Presentation type：Oral presentation (general)
-
アルギニンメチル化転移酵素PRMT5によるHSP90A活性調節機構
市川朝永、Obeid Shanab、中畑新吾、伊波英克、尾野雅哉、中武彩子、阪本訓代、森下和広
第21回造血器腫瘍研究会
Event date： 2017.2.17 - 2017.2.18
Language：Japanese Presentation type：Oral presentation (general)
Awards 【 display / non-display 】
-
第50回宮崎日日新聞賞・科学賞
2014.10 宮日新聞
森下和広
Award type：Award from publisher, newspaper, foundation, etc. Country：Japan
-
日本白血病基金セゾン賞
2006.4 日本白血病基金
森下和広
Award type：Award from publisher, newspaper, foundation, etc. Country：Japan
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
NDRG2欠損による代謝異常に依存した成人T細胞白血病発症機構の解明
Grant number：22H02831 2022.04 - 2025.03
独立行政法人日本学術振興会 科学研究費補助金 基盤研究(B)
Authorship：Principal investigator
-
低侵襲・効率的な胎内サイトメガロウイルス感染症診断のための新たなアルゴリズム開発
Grant number：21K09452 2021.04 - 2025.03
独立行政法人日本学術振興会 科学研究費補助金 基盤研究(C)
金子 政時、
Authorship：Coinvestigator(s)
-
ペルーにおけるHTLV-1重複感染による高頻度ATL発症の比較ゲノム解析
2017 - 2020.03
科学研究費補助金 基盤研究(B)
Authorship：Principal investigator
-
癌化につながるNDRG2欠損に依存した新規ストレス情報伝達制御異常
2017 - 2020.03
科学研究費補助金 基盤研究(B)
Authorship：Principal investigator
-
腸内細菌叢異常に伴うHTLV-1キャリアからATL発症過程解析
2015.04 - 2017.03
科学研究費補助金 挑戦的萌芽研究
Authorship：Principal investigator
腸内細菌叢異常に伴うHTLV-1キャリアからATL発症過程解析